The latest lymphoma news
Researchers uncover mechanism that fuels growth of aggressive B-cell lymphoma
Researchers from the University of Helsinki and HUS investigated the effects of recurring mutations in…
Browsing: Lymphoma
Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for adult relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r ALL)
This content is password-protected. To view it, please enter the password below. Password:
ASCO 2024: Novel therapy combination more effective at treating Hodgkin lymphoma than established treatment
A new study showed that BrECADD, a novel therapy combination, cured classic Hodgkin lymphoma more…
FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma
On May 30, 2024, the US Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno…
Blood samples enhance B-cell lymphoma diagnostics and prognosis
B-cell lymphoma is the most common cancer of the lymphatic system. In roughly 30% of…
New AI model detects 90% of lymphatic cancer cases
Medical image analysis using AI has developed rapidly in recent years. Now, one of the…
Some lymphomas become resistant to treatment; Gene discovery may offer path to overcome it
Patients with some types of lymphoma that become resistant to standard treatments may benefit from…
New AI model detects ninety percent of lymphatic cancer cases
Medical image analysis using AI has developed rapidly in recent years. Now, one of the…
FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib with…
Researchers identify key characteristics associated with improved CAR T outcomes in large B cell lymphoma
Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain…